Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Shares Issued (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Shares Issued data on record, last reported at $605000.0 in Q4 2025.

  • For Q4 2025, Shares Issued rose 119.23% year-over-year to $605000.0; the TTM value through Dec 2025 reached $1.5 million, down 10.32%, while the annual FY2025 figure was $1.5 million, 10.32% down from the prior year.
  • Shares Issued reached $605000.0 in Q4 2025 per SNDX's latest filing, up from $465000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $162.0 million in Q4 2022 and bottomed at -$73.3 million in Q2 2021.
  • Average Shares Issued over 5 years is $12.8 million, with a median of $505000.0 recorded in 2022.
  • The widest YoY moves for Shares Issued: up 117087.5% in 2021, down 5586.53% in 2021.
  • A 5-year view of Shares Issued shows it stood at $81.2 million in 2021, then surged by 99.51% to $162.0 million in 2022, then tumbled by 99.95% to $84000.0 in 2023, then crashed by 3845.24% to -$3.1 million in 2024, then soared by 119.23% to $605000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $605000.0 in Q4 2025, $465000.0 in Q3 2025, and -$77000.0 in Q2 2025.